Biologics

Bio & Pharma Samsung Biologics bags $514 mn CMO contract from US pharma

Samsung Biologics Co., the world’s largest contract manufacturing organization (CMO), said on Monday it has secured a $5.14 million order from...

Bio & Pharma Chong Kun Dang to build new plant for foray into biologics market

Chong Kun Dang Pharmaceutical Corp. is discussing building a research center and a plant in Siheung, about 30 kilometers southwest of Seoul, with th...

Korean stock market Samsung Biologics shares fly high to be Korea’s third most valuable firm

Samsung Biologics Co., the world’s largest contract drugmaker, has become South Korea’s third most valuable stock on the country’s...

Earnings Samsung Biologics posts record 2024 sales, operating profit as it goes global

South Korea's Samsung Biologics Co., the world’s largest contract drugmaker, on Wednesday posted its largest-ever annual sales and operating p...

Bio & Pharma Lotte Biologics eyes first ADC CDMO order in 2025

SAN FRANCISCO -- Lotte Biologics Co., the drug consignment development and production unit of South Korean conglomerate Lotte Group, will seek to wi...

Bio & Pharma Samsung Biologics signs $1.4 bn CMO deal with European pharma

South Korea's Samsung Biologics Co., the world’s largest contract drugmaker, said on Tuesday it signed a $1.4 billion contract manufacturing o...

Bio & Pharma Samsung Biologics signs initial deal with LigaChem Bio on ADC production

Samsung Biologics Co., the world’s largest contract drugmaker, said on Thursday it has signed an initial agreement with LigaChem Biosciences I...

Bio & Pharma Samsung Biologics wins $668 million CDMO deal with European pharma

Samsung Biologics Co., the world’s largest contract drugmaker, said on Wednesday it has signed two drug manufacturing contracts worth a combin...

Bio & Pharma IMBiologics transfers autoimmune disease drug tech to Huadong Pharma

South Korea's antibody-based biotech company IMBiologics announced on Friday that it signed a contract to transfer the technology of its autoimmune ...

Korean stock market Biotech stocks, foreigners’ top pick in Korea amid panic selling

Foreigners and institutional investors in the South Korean stock market picked biotechs as their favorite shares in hopes of a biopharma stock jump ...

Bio & Pharma Samsung’s biotech duo on a roll with $1.1 bn CMO order

Samsung Group is on track to rise to the top of biosimilar companies in the world and become South Korea’s largest drug maker for contract man...

Bio & Pharma Lotte Biologics targets $1.1 billion in sales with new bio plants

South Korean biopharmaceutical company Lotte Biologics Co. said on Wednesday it is aiming for 1.5 trillion won ($1.1 billion) in annual sales by 203...

Bio & Pharma Samsung Biologics eyes windfall gain amid US-China row

SAN DIEGO – Samsung Biologics Co. is enjoying a stream of contract development and manufacturing order inquiries from big pharmaceutical compa...

Bio & Pharma Samsung Biologics signs ADC CDO deal with LegoChem Bio

Samsung Biologics Co. has agreed with South Korean biotech company LegoChem Biosciences Inc. to provide contract development organization (CDO) serv...

Bio & Pharma Lotte Biologics, NJ Bio to jointly develop ADC

South Korea's Lotte Biologics Co. announced on Monday that it has signed a strategic business agreement with NJ Bio, a US-based preclinical and clin...

Bio & Pharma Samsung Biologics reaches record-breaking annual orders

Samsung Biologics Co., the world’s top contract manufacturing organization (CMO) by capacity, surpassed the annual contract manufacturing orde...

Bio & Pharma Lotte builds US antibody-drug conjugate plant with $82 mn

South Korea’s Lotte Biologics Co. is establishing an antibody-drug conjugate (ADC) factory in Syracuse, New York, with an investment of 110 bi...

Bio & Pharma Samsung Biologics eyes new drugmaker acquisitions

BARCELONA -- Samsung Biologics Co., the world’s top contract manufacturing organization by capacity, is looking for acquisitions of new drugma...

Bio & Pharma Samsung Biologics partners with Europe's largest VC

Samsung Biologics Co., the world's largest contract drug manufacturer, announced on Tuesday it has teamed up with global biotech venture capitalist ...

Bio & Pharma Hanmi Pharma’s Phase 3 trials for anti-obesity medicine approved

South Korea’s Hanmi Pharmaceutical Co. on Monday said the Ministry of Food and Drug Safety approved Phase 3 clinical trials for the company&...

Bio & Pharma Lotte Biologics to break ground on 1st local CDMO plant in 2024

South Korea’s Lotte Biologics Co. is set to start building its first local facility for drug manufacturing next year, aiming for 400,000 liter...

Bio & Pharma Prestige Biologics partners with Indian company for CDMO

Prestige Biologics Co., a South Korean biopharmaceutical contract development and manufacturing organization (CDMO) company, is expanding its CDMO b...

Bio & Pharma Samsung Biologics wins $242 mn order from Bristol Myers Squibb

Samsung Biologics Co., the world’s largest contract drugmaker, said on Monday it has signed an agreement to produce $242 million worth of anti...

Bio & Pharma SK Pharmteco gears up for big leap in advanced biotherapies

SK Pharmteco Co., South Korean conglomerate SK Group’s contract development and manufacturing organization (CDMO), is upping the ante in its b...

Bio & Pharma Novomics expands presence in Chinese cancer market

South Korean molecular diagnostics company Novomics Co. announced on Wednesday that it has signed a collaboration agreement with Chinese molecular d...

Bio & Pharma Novartis $391 mn deal powers Samsung Biologics backlogs to record high

Samsung Biologics Co., the world’s top contract manufacturing organization by capacity, inked a $391 million contract from Novartis, nearly fi...

Carbon neutrality Samsung Biologics, Celltrion pledge major CO2 cuts

South Korea’s No. 1 biopharmaceutical company Samsung BioLogics Co. and No. 2 Celltrion Inc. produced higher CO2 emissions last year than in 2...

Bio & Pharma Samsung Biologics wins $897 mn in two deals with Pfizer

Samsung Biologics Co., the world’s largest contract manufacturing organization (CMO) in terms of production capacity, said on Tuesday it has w...

Bio & Pharma Samsung Biologics, Pfizer sign $411.3 mn agreement for long-term CDMO

Samsung Biologics Co., the world’s No. 1 contract drugmaker, announced a groundbreaking strategic partnership with Pfizer on Thursday, marking...

Bio & Pharma Samsung Biologics to double production by 2032; eyes ADCs, M&As

BOSTON – Samsung Biologics Co., the world’s No. 1 contract drugmaker, plans to more than double its total annual production capacity to ...